Literature DB >> 9092315

Escherichia coli O157:H7 diarrhea in the United States: clinical and epidemiologic features.

L Slutsker1, A A Ries, K D Greene, J G Wells, L Hutwagner, P M Griffin.   

Abstract

BACKGROUND: Escherichia coli O157:H7 is increasingly recognized as a cause of bacterial diarrhea in the United States, but the frequency of its isolation and the clinical and epidemiologic features of E. coli O157:H7 infection in a large, geographically diverse population of patients have not been well described.
OBJECTIVE: To determine the frequency of isolation of E. coli O157:H7 relative to that of other bacterial enteric pathogens in a nationwide sample of patients and to identify the clinical and epidemiologic features of E. coli O157:H7 infection.
DESIGN: Population prevalence study from October 1990 to October 1992.
SETTING: 10 U.S. hospitals. PATIENTS: Both inpatients and outpatients who had stool samples submitted to 1 of 10 laboratories for routine pathogen identification. MEASUREMENTS: Clinical, epidemiologic, and laboratory information was collected for infected and uninfected patients. Isolates of E. coli O157:H7 were tested for production of Shiga toxin. Patient charts were then reviewed.
RESULTS: Escherichia coli O157:H7 was isolated from 118 (0.39%) of the 30463 fecal specimens tested. The proportion of fecal specimens with isolates was higher at northern sites (0.57%) than at southern sites (0.13%) (P < 0.001). Escherichia coli O157:H7 was more likely to be isolated from visibly bloody stool specimens than from specimens without visible blood (odds ratio [OR], 59.2 [95% CI, 36.6 to 96.0) and was the pathogen most commonly isolated from visibly bloody stool specimens that yielded a bacterial enteric pathogen (39% of such specimens). The highest age-specific isolation proportions from fecal specimens for E. coli O157:H7 were in patients 5 to 9 years of age (0.90%) and 50 to 59 years of age (0.89%). Clinical features independently associated with E. coli O157:H7 infection compared with the other enteric pathogens included a history of bloody diarrhea (OR, 18.6 [CI, 7.4 to 48.6]), visibly bloody stool specimens (OR, 8.1 [CI, 3.6 to 18.3]), no reported fever (OR, 8.3 [CI, 1.6 to 50.0]), leukocyte count greater than 10 x 10(9)/L (OR, 4.0 [CI, 1.7 to 9.5]), and abdominal tenderness on physical examination (OR, 2.9 [CI, 1.2 to 7.2]).
CONCLUSIONS: In some geographic areas and some age groups, isolation proportions from fecal specimens for E. coli O157:H7 surpassed those of other common enteric pathogens. One third of isolates of this organism came from nonbloody specimens. Because person-to-person transmission of E. coli O157:H7 is not uncommon and infection with this organism may cause severe disease, stool specimens from all patients with a history of acute bloody diarrhea should be cultured for E. coli O157:H7.

Entities:  

Mesh:

Year:  1997        PMID: 9092315     DOI: 10.7326/0003-4819-126-7-199704010-00002

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  66 in total

1.  Increase in acid tolerance of Campylobacter jejuni through coincubation with amoebae.

Authors:  Diana Axelsson-Olsson; Lovisa Svensson; Jenny Olofsson; Paulo Salomon; Jonas Waldenström; Patrik Ellström; Björn Olsen
Journal:  Appl Environ Microbiol       Date:  2010-05-07       Impact factor: 4.792

2.  Restriction-site-specific PCR as a rapid test to detect enterohemorrhagic Escherichia coli O157:H7 strains in environmental samples.

Authors:  R Kimura; R E Mandrell; J C Galland; D Hyatt; L W Riley
Journal:  Appl Environ Microbiol       Date:  2000-06       Impact factor: 4.792

3.  Comparison of sorbitol MacConkey agar and a two-step method which utilizes enzyme-linked immunosorbent assay toxin testing and a chromogenic agar to detect and isolate enterohemorrhagic Escherichia coli.

Authors:  T J Novicki; J A Daly; S L Mottice; K C Carroll
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

4.  Role of the laboratory in the diagnosis of enterohemorrhagic Escherichia coli infections.

Authors:  Sue C Kehl
Journal:  J Clin Microbiol       Date:  2002-08       Impact factor: 5.948

5.  Shiga toxin 2 and flagellin from shiga-toxigenic Escherichia coli superinduce interleukin-8 through synergistic effects on host stress-activated protein kinase activation.

Authors:  Dakshina M Jandhyala; Trisha J Rogers; Anne Kane; Adrienne W Paton; James C Paton; Cheleste M Thorpe
Journal:  Infect Immun       Date:  2010-05-03       Impact factor: 3.441

6.  Monitoring of stool microbiota in subjects with diarrhea indicates distortions in composition.

Authors:  Volker Mai; Christopher R Braden; Jill Heckendorf; Baiba Pironis; Jon Mark Hirshon
Journal:  J Clin Microbiol       Date:  2006-10-04       Impact factor: 5.948

7.  Chemokine expression in the monocytic cell line THP-1 in response to purified shiga toxin 1 and/or lipopolysaccharides.

Authors:  Lisa M Harrison; Christel van den Hoogen; Wilhelmina C E van Haaften; Vernon L Tesh
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

8.  A DNA vaccine encoding the enterohemorragic Escherichia coli Shiga-like toxin 2 A2 and B subunits confers protective immunity to Shiga toxin challenge in the murine model.

Authors:  Leticia V Bentancor; Marcos Bilen; Romina J Fernández Brando; María Victoria Ramos; Luis C S Ferreira; Pablo D Ghiringhelli; Marina S Palermo
Journal:  Clin Vaccine Immunol       Date:  2009-01-28

9.  Evaluation of performance and potential clinical impact of ProSpecT Shiga toxin Escherichia coli microplate assay for detection of Shiga Toxin-producing E. coli in stool samples.

Authors:  Patrick J Gavin; Lance R Peterson; Anna C Pasquariello; Joanna Blackburn; Mark G Hamming; Kuo J Kuo; Richard B Thomson
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

Review 10.  Diagnosis and treatment of bacterial diarrhea.

Authors:  James V Lawler; Mark R Wallace
Journal:  Curr Gastroenterol Rep       Date:  2003-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.